Targeting a specific metabolic pathway to improve cognitive function in cancer survivors
PQ#12; Targeting Nampt-mediated NAD+ metabolism in chemobrain
This study is looking at how chemotherapy, especially with a drug called cisplatin, can affect memory and thinking in cancer survivors, and it aims to find ways to help improve brain function by boosting a substance called NAD+ with a supplement called NMN.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10693068 on NIH RePORTER |
What this research studies
This research investigates how chemotherapy can lead to cognitive dysfunction, commonly referred to as chemobrain, in cancer survivors. It focuses on understanding the molecular mechanisms behind this condition, particularly the role of the Nampt-mediated NAD+ metabolic pathway. By using the chemotherapy drug cisplatin, the study explores how it affects brain function and memory. The researchers aim to find therapeutic strategies, such as increasing NAD+ levels with a precursor called nicotinamide mononucleotide (NMN), to potentially reverse cognitive impairments caused by chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer survivors experiencing cognitive difficulties following chemotherapy.
Not a fit: Patients who have not undergone chemotherapy or do not experience cognitive impairments related to cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that alleviate cognitive dysfunction in cancer survivors.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways to improve cognitive function, suggesting potential for success in this novel approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Jang, Mi-Hyeon — Rutgers Biomedical and Health Sciences
- Study coordinator: Jang, Mi-Hyeon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.